After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
The Breakwater study hits on overall survival with "unprecedented" data.
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
The combined company's MALT1 inhibitor has started phase 1.
